THE ARISING · Longevity & Healthspan
Lilly's Zepbound and Foundayo Come to Hims at Self-Pay Prices
Eli Lilly's obesity drugs Zepbound and Foundayo will now be offered through the Hims & Hers telehealth platform, with Foundayo starting at $149 a month and Zepbound at $299.
The companies announced the deal on November 6, in a joint company announcement. Patients who are eligible and have a prescription can use Hims to get Lilly's drugs at the same "self-pay" prices available elsewhere. Self-pay means the patient pays directly, without going through insurance.
The announced starting medication prices are $149 per month for Foundayo and $299 for Zepbound. These figures are not verified all-in costs: dose, eligibility and any separate care or platform fees may affect what a patient pays.
For people weighing obesity treatment, the agreement offers another route to approved Lilly medicines. A licensed clinician must determine whether treatment is appropriate.
Whether more approved GLP-1 drugs reach telehealth platforms at self-pay prices, and how those prices move from their starting points.